Encontre seu próximo podcast favorito

Torne'se membro hoje e leia gratuitamente por 30 dias.
What Next: The Price of a Peanut Allergy: There are currently no FDA-approved treatments for a peanut allergy. A new drug was just recommended for approval.

What Next: The Price of a Peanut Allergy: There are currently no FDA-approved treatments for a peanut allergy. A new drug was just recommended for approval.

A partir deSlate Daily Feed


What Next: The Price of a Peanut Allergy: There are currently no FDA-approved treatments for a peanut allergy. A new drug was just recommended for approval.

A partir deSlate Daily Feed

avaliações:
Comprimento:
21 minutos
Lançado em:
Sep 19, 2019
Formato:
Episódio de podcast

Descrição

A buzzy new drug to help treat people with a peanut allergy was recommended for approval by an FDA advisory board this week. It would be the first government-approved method intended to combat these kinds of allergic reactions. The story behind that drug helps explain how the cost of many prescription drugs ends up being so high.
Guest: James Hamblin, staff writer at The Atlantic.
Slate Plus members get bonus segments and ad-free podcast feeds. Sign up now.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Lançado em:
Sep 19, 2019
Formato:
Episódio de podcast